CAN CD 133 CELLS PREVENT HYPOXIA DRIVEN RETINAL NEOVASCULARISATION IN A RODENT MO

描述（由申请人提供）：眼部血管生成的临床意义是巨大的，因为在西半球，糖尿病视网膜病变引起的视网膜新生血管是年轻患者新发失明的最常见原因，而黄斑变性引起的脉络膜新生血管（CNV）是老年患者严重且不可逆视力丧失的主要原因。在过去的几年里，血管生成研究领域取得了很大的进展，这一假设的推动下，抑制血管生成将是一个有用的策略，许多眼部疾病，其中病理性血管生成起作用。视网膜新生血管包括视网膜血管的芽的发育，芽通常穿透内限制膜（ILM）并生长到玻璃体中。在缺血性视网膜病变中，如糖尿病视网膜病变、早产儿视网膜病变、中央静脉闭塞和视网膜分支静脉闭塞，均可观察到视网膜新生血管的形成。抑制血管增殖是当前市场技术所采用的策略，并导致大量药物试图以新生血管为目标。即使这些药物在短期内抑制眼部血管生成并缓解症状方面取得了一定程度的成功，但作为初始原因的潜在血管丧失仍未得到治疗。此外，抗血管生成药物的长期效果尚不清楚。然而，可以假设它们可能导致血管损失加剧，这是新血管形成的沉淀事件。治疗性干细胞是一项正在开发的相关新技术，以克服几种现有技术的缺点。在小鼠视网膜新生血管模型中，造血干细胞已被证明可以挽救异常的视网膜血管形成。Arteriocyte的核心业务专注于开发“现成的”干细胞产品，用于治疗血管生成应用。在这项研究中，该公司提出探索cd133成血管细胞作为一种细胞类型的特异性使用，以挽救视网膜血管闭塞并减少糖尿病视网膜病变的新生血管影响。

DESCRIPTION (provided by applicant): The clinical significance of ocular angiogenesis is enormous, due to the fact that in the western hemisphere, retinal neovascularization resulting from diabetic retinopathy is the most common cause of new blindness in young patients, and choroidal neovascularization (CNV) resulting from AMD is the chief cause of severe and irreversible loss of vision in elderly patients. Over the past several years, much progress has been made in the field of angiogenesis research, fueled by the hypothesis that inhibition of angiogenesis would be a useful strategy to a number of ocular diseases in which pathologic angiogenesis plays a role. Retinal neovascularization involves the development of sprouts from retinal vessels, which usually penetrates the inner limiting membrane (ILM) and grows into the vitreous. Retinal neovascularization is observed in ischemic retinopathies such as diabetic retinopathy, retinopathy of prematurity, central vein occlusion and branch retinal vein occlusion. The inhibition of vessel proliferation is the strategy utilized by current market technologies and has led to the presence of a plethora of drugs attempting to target neovascularization. Even if the efforts of these drugs become somewhat successful in inhibiting ocular angiogenesis for the short term and bring symptomatic relief, the underlying vascular loss that is the initiating cause remains untreated. In addition the long-term effects of anti-angiogenic drugs are unclear. It can be assumed however that they might lead to the exacerbation of vessel loss, the precipitating event for neovascularization. Therapeutic stem cells is a relevant new technology being developed to overcome the shortcomings of several current technologies. Hematopoietic stem cells have been shown to rescue abnormal retinal vascularization in a murine model of retinal neovascularization. Arteriocyte's core business is focused on developing `off-the shelf' stem cell-based products for therapeutic angiogenesis applications. In this study the company proposes to explore the specific use of CD 133 hemangioblast as a cell type to rescue retinal vessel obliteration and diminish the neovascular effects of diabetic retinopathy.